Infliximab for psoriasis and psoriatic arthritis

Clinical and Experimental Rheumatology

Volumn 20, Issue 6 SUPPL. 28, 2002, Pages

  Antoni, Christian ^a   Manger, Bernhard ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Infliximab; Psoriasis; Psoriatic arthritis; Safety; Treatment

Indexed keywords

ANTIRHEUMATIC AGENT; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; MONOCLONAL ANTIBODY;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; HUMAN; MONOTHERAPY; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; SKIN DEFECT; SPONDYLOARTHROPATHY; SYNOVITIS; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; HUMANS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS;

EID: 1842854945     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. CHAUDHARI U, ROMANO P, MULCAHY LD, DOOLEY LT, BAKER DG, GOTTLIEB AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-7.
2. OGILVIE AL, ANTONI C, DECHANT C et al.: Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001; 144: 587-9.
3. SCHOPF RE, AUST H, KNOP J: Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002; 46: 886-91.
4. O'QUINN RP, MILLER JL: The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: A report of 2 cases. Arch Dermatol 2002; 138: 644-8.
5. KIRBY B, MARSLAND AM, CARMICHAEL AJ, GRIFFITHS CE: Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 2001; 26: 27-9.
6. ANTONI C, DECHANT C, LORENZ HM et al.: Open-label study of infliximab treatment for psoriatic arthritis: Clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Care Res 2002; in press.
7. CLEGG DO, REDA DJ, MEJIAS E et al.: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39: 2013-20.
8. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
9. VAN DEN BOSCH F, KRUITHOF E, BAETEN D et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002; 46: 755-65.
10. VAN DEN BOSCH F, KRUITHOF E, BAETEN D, DE KEYSER F, MIELANTS H, VEYS EM: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000; 59: 428-33.
11. GRIFFITHS CE: Immunotherapy for psoriasis: From serendipity to selectivity. Lancet 2002; 359: 279-80.
12. SCALLON BJ, MOORE MA, TRINH H, KNIGHT DM, GHRAYEB J: Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7: 251-9.
13. BARONE D, KRANTZ C, LAMBERT D, MAGGIORA K, MOHLER K: Comparative analysis of the ability of etanercept and infliximab to lyse TNF-expressing cells in a complement dependent fashion. Arthritis Rheum 1999; 42: S90.
14. SCALLON B, CAI A, SOLOWSKI N et al.: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418-26.